EBC-46 - EBC46 Research Hub (Page 9)

EBC-46

Patient Selection in EBC-46 Trials: Who Qualifies and Why Tumour Accessibility Matters

Not every cancer patient qualifies for EBC-46 clinical trials. Tumour accessibility, prior treatment history, and lesion characteristics all determine eligibility — here is what the inclusion criteria reveal.

Fluorescent microscopy image showing cellular disruption and vascular effects at the tumour level

EBC-46

Vascular Disruption Without Systemic Toxicity: How EBC-46 Starves Tumours From Within

EBC-46 destroys the blood vessels feeding a tumour within hours of injection — cutting off oxygen and nutrients while leaving surrounding healthy vasculature intact. Here is the biology behind this precision.

Government regulatory building symbolising FDA and EMA drug approval pathways

EBC-46

Compassionate Use Pathways for Tigilanol Tiglate: How Patients Access Unapproved Cancer Drugs

Compassionate use and expanded access programmes could allow cancer patients to receive tigilanol tiglate before formal Phase III approval — here is how the regulatory framework works.

EBC-46

Hylandia dockrillii vs Fontainea picrosperma: The Blushwood Misidentification That Has Misled the Internet for a Decade

Two plants share the name Blushwood, but only one contains EBC-46. A decade of media misidentification has wrongly attributed tigilanol tiglate to Hylandia dockrillii — here is the full story.

Person applying natural botanical extract to skin as part of a wellness skincare routine

EBC-46

Topical Blushwood Berry Extract: What Users Report and What the Science Says

Verified buyers report striking results with blushwood berry extract — from inflammation and energy to skin changes and outcomes that surprised their doctors. Science should be paying attention.

Dense Australian tropical rainforest canopy with filtered light through lush green leaves

EBC-46

Fontainea picrosperma: The Rainforest Tree That Produces EBC-46

Fontainea picrosperma grows only in north Queensland's Wet Tropics and produces a pharmacologically extraordinary compound. The full extent of what it can do remains one of botany's most compelling open questions.

Clinical trial setting with medical researcher reviewing patient data in hospital

EBC-46

EBC-46 in Human Clinical Trials: Phase I Safety Data and What It Tells Us

Phase I human trials of tigilanol tiglate are evaluating safety in solid tumours. Early data suggests the tolerability profile mirrors what was observed in veterinary studies.

Scientist examining molecular structures under laboratory microscope for cancer research

EBC-46

PKC-Delta Activation: The Molecular Switch Behind EBC-46's Anti-Tumour Effect

EBC-46 works by mimicking diacylglycerol to activate PKC-delta, triggering a cascade of vascular disruption and immune recruitment that destroys tumours from within.

Medical regulatory documents and FDA approval paperwork on a clinical desk

EBC-46

Stelfonta's FDA Approval: What the Regulatory Pathway Tells Us About EBC-46's Future

Stelfonta became the first tigilanol tiglate product approved by the FDA. Understanding its regulatory journey maps the path EBC-46 must follow for human approval.

Molecular biology research diagram representing pharmacokinetics and drug distribution mechanisms

EBC-46

Tigilanol Tiglate Pharmacokinetics: What Happens After an EBC-46 Injection?

Intratumoral EBC-46 is designed to stay local — but how much reaches systemic circulation, and what does the body do with it? A detailed look at tigilanol tiglate pharmacokinetics.

Pharmaceutical laboratory drug development research representing FDA orphan drug designation process

EBC-46

Orphan Drug Designation and EBC-46: What It Means for Patients with Rare Cancers

EBC-46 has received Orphan Drug Designation from the FDA for specific rare cancers. Here's what that regulatory milestone actually means — and why it matters for patients.

Immunology laboratory research showing immune cell interaction with cancer cells

EBC-46

The Abscopal Effect and EBC-46: Can Intratumoral Treatment Trigger Systemic Immune Response?

When a local injection shrinks tumours far from the injection site, something remarkable is happening. Here's what research reveals about EBC-46 and systemic anti-tumour immunity.

See all